Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) has appointed David Goldstein as chief advisor for its ambitious genomics initiative.
Professor Goldstein will continue in his full-time role at the USA’s Columbia University Medical Center, where his roles include director of the Institute for Genomic Medicine and professor of genetics and development.
He is renowned for his research on human genetic diversity, the genetics of disease and pharmacogenetics, and will be responsible for driving the scientific progress of AstraZeneca’s genomics initiative, created to transform drug discovery and development across the entire research and development pipeline.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze